Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA

Xiaomo Xiong,Jeff Jianfei Guo

DOI: https://doi.org/10.1007/s40273-024-01453-0

2024-11-23

PharmacoEconomics

Abstract:Treating unresectable hepatocellular carcinoma (uHCC) is challenging. Clinical trials have shown that Single Tremelimumab Regular Interval Durvalumab (STRIDE) offers clinical benefits as a first-line treatment for uHCC, but its cost effectiveness remains unknown in the USA.

pharmacology & pharmacy,health care sciences & services,health policy & services,economics